Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.38 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8875809 | 1.00 | MEN1 (0.38) | MEN1KMT2ATP53HSD17B10KDM4E | |
| SCHEMBL9232942 | 0.89 | KMT2A (0.38) | MEN1KMT2ATP53HSD17B10KDM4E | |
| Fumaric Acid SCHEMBL8874318 | 0.83 | CYP3A4 (0.41) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| Fumaric Acid SCHEMBL8874309 | 0.83 | CYP3A4 (0.41) | MEN1KMT2AHSD17B10KDM4EALDH1A1 | |
| Fumaric Acid SCHEMBL8874351 | 0.81 | MITF (0.40) | MEN1KMT2ATP53HSD17B10ALDH1A1 | |
| Fumaric Acid SCHEMBL8874359 | 0.81 | MITF (0.40) | MEN1KMT2ATP53HSD17B10ALDH1A1 | |
| Fumaric Acid SCHEMBL8874476 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2ATP53HSD17B10KDM4E | |
| Fumaric Acid SCHEMBL8874480 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2ATP53HSD17B10KDM4E | |
| SCHEMBL8874931 | 0.75 | MAPK1 (0.48) | MEN1KMT2ATP53KDM4EALDH1A1 | |
| Fumaric Acid SCHEMBL8873381 | 0.73 | BCHE (0.34) | MEN1KMT2ATP53HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5646173-A | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-08 | — | — | US | disclosed |